anaplastic large cell lymphoma

May 21, 2019

FDA Won’t Ban Sales of Breast Implants Linked to Lymphoma, But Considers Black Box Warning

News

In announcing that breast implants linked to anaplastic large-cell lymphoma (ALCL) can continue to be sold in the United States, the U.S. Food and Drug Administration (FDA) proposed assurances that the ... Read more

February 14, 2019

FDA Update Shows 457 Cases of ALCL Linked to Breast Implants

News

The number of reported cases of anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) has risen to 457, according to a 2018 update from the U.S. Food and Drug Administration ... Read more

September 13, 2018

Mouse Study Finds Potential Therapeutic Target for Anaplastic Large-cell Lymphoma

News

A cellular protein called TYK2 plays a key role in tumor development and survival in anaplastic large-cell lymphoma (ALCL), according to a new study. The finding suggests that targeting TYK2 ... Read more

May 31, 2018

Xalkori Named Breakthrough Therapy for Difficult-to-Treat Rare Lymphoma

News

The U.S. Food and Drug Administration granted breakthrough therapy designation to Pfizer’s Xalkori (crizotinib) for the treatment of a subgroup of difficult-to-treat systemic anaplastic large cell lymphoma (ALCL). The FDA’s ... Read more

May 15, 2017

Adding Etoposide Improves Survival in Middle-aged and Older Lymphoma Patients, Study Reports

News

Adding etoposide to a treatment regimen called CHOP led to longer survival times for middle-aged and older people with a certain kind of lymphoma, a Scandinavian study reported. The results ... Read more

April 8, 2016April 8, 2016

Patient-reported Outcomes in Lymphoma Clinical Trials Are Recognized as Important Tools

News

Patient-reported outcomes in clinical trials of brentuximab vedotin for Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) show improvements in patients’ health-related quality of life, emphasizing their importance for patient management ... Read more

January 20, 2016January 20, 2016

ALC Lymphoma’s Origin Traced to the Thymus, Raising Treatment Possibilities

News

Researchers in the U.K. have traced the origins of anaplastic large cell lymphoma (ALCL) to the thymus, raising the possibility that new treatments may be designed to more effectively prevent ALCL relapse. Their study was published in Nature Communications. ALCL is ... Read more

January 14, 2016January 14, 2016

Origins of Aggressive Childhood Lymphona Found, Offering Hope for New Treatments

News

Researchers at the University of Cambridge in the U.K. say they have traced the origins of anaplastic large cell lymphoma (ALCL), finding that the malignancy originates in early cells of the thymus, ... Read more

December 4, 2015December 4, 2015

Breast Implant-linked Lymphomas Best Treated by Surgical Removal, Study Finds

News

According to the results of an international study led by researchers at The University of Texas MD Anderson Cancer Center, the optimal treatment for most women with breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) ... Read more